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PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including col-
orectal cancer (CRC). Mutations of PIK3CA have been reported in 10–20% of CRC, about
80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC,
PIK3CA mutations have been associated with a worse clinical outcome and with a negative
prediction of a response to targeted therapy by anti-EGFR monoclonal antibodies. How-
ever, these findings have not been confirmed in all studies and subsequent more detailed
analysis has revealed that these effects may be restricted to mutations in Exon 20. Finally,
mutations in PIK3CA may be the long sought biomarker for successful adjuvant therapy
with aspirin in patients with CRC. Therefore, PIK3CA mutations appear to be a promising
predictive biomarker; however, further data are needed to conclusively define the impact
of somatic mutations in the PIK3CA gene for the management of patients with CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy
worldwide, affecting more than 1.2 million patients and leads to
over 6,000,000 deaths every year (1). Since the seminal paper
by Kinzler and Vogelstein in 1996, it is known that the devel-
opment of CRC is based on an accumulation of hereditary and
somatic genetic alterations ultimately leading to the malignant
phenotype (2). The development of CRC through adenomatous
precursor lesions has further led to secondary prevention strat-
egy of colonoscopy screening. In addition, a large body of work
has finally shown that CRC is not a single disease but a heteroge-
neous group of neoplasms with a different genetic and epigenetic
background. A number of molecular classifications have been sug-
gested and the presence of at least three pathways are generally
accepted today, including the chromosomal instability pathway
(CIN), the microsatellite instability pathway (MSI), and the epige-
netic CpG island methylator phenotype (CIMP) (3). Despite this
increasing body of knowledge, the therapeutic options in patients
with advanced, metastatic disease remains rather restricted, and
the prognosis poor. The introduction of new targeted therapeu-
tics, namely the development of antibodies against the epidermal
growth factor receptor (EGFR), has raised new hope for success-
ful treating of advanced CRC (4). However, only a subgroup of
patients, especially those with a KRAS wild-type tumor, profit from
the anti-EGFR therapy (5). Unfortunately, KRAS wild-type is not
sufficient to predict clinical response and mutations in other effec-
tors of the KRAS or KRAS related pathway have been anticipated
to be predictive for anti-EGFR response. A promising candidate
for this prediction is PIK3CA, which may not only be predictive
for targeted therapy by anti-EGFR antibodies but also turned out
to be probably a positive biomarker for the neoadjuvant use of
aspirin.
BASIC BIOLOGY OF PI3K AND PIK3CA
The phosphatidylinositol-3-kinase (PI3K) belongs to a fam-
ily of heterodimeric lipid kinases consisting of a regulatory
and a catalytic subunit, phosphorylating phosphatidylinositol,
an important cell membrane element and second messenger
involved in cell signaling (6). Activated by various receptor tyro-
sine kinases, EGFR, human EGFR 2 (HER2), insulin growth fac-
tor (IGF-1R), and platelet derived growth factor (PDGFR), the
PI3K promotes and regulates various cellular processes, includ-
ing proliferation, survival, apoptosis, migration, and metabolism
(Figure 1). PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha), the catalytic p110-alpha subunit
of PI3K, has been described to be commonly mutated in various
cancer, including glioblastoma, gastric, breast, ovary, lung, and
CRC (7, 8). More than 80% of mutations detected in PIK3CA
were reported in two hotspots, the helicase domain of exon 9
(codon 542 and 545) and the kinase domain in exon 20 (codon
1047) (8). Downstream effectors of the PI3K pathway include AKT
(protein kinase B), a serine–threonine kinase, directly activated by
PI3K and the mTOR (mammalian target of rapamycin), another
serine–threonine kinase leading to an increased translation of var-
ious mRNAs encoding cell cycle regulators, including MYC and
cyclin D1 and a potential target of therapeutic inhibition (9). In
the PI3K/AKT/mTOR pathway, the tumor suppressor gene PTEN
(phosphatase and tensin homolog deleted on chromosome 10) is
a direct antagonist and mutation or loss of PTEN expression has
shown to be correlated with a poor outcome in CRC (10, 11).
FREQUENCY AND PROGNOSTIC IMPACT OF PIK3CA
MUTATION IN COLORECTAL CANCER
Roughly, PIK3CA mutation has been reported to be present in
10–20% of CRC. Variation in the frequency has been observed
in large population based studies compared to clinical studies
(12). In addition, as expected, the technique used to evaluate the
PIK3CA mutation has a direct impact on the frequency of muta-
tion observed and using pyrosequencing, generally considered a
more sensitive assay, shows higher incidence of PIK3CA mutations
(15–18%) (13–15) compared to Sanger sequencing (11–12%) (16–
18). Mutations are more commonly found in exon 9 compared to
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FIGURE 1 | Schematic overview of PIK3CA related cell signaling
pathways in colorectal cancer. AA, arachidonic acid; AKT, protein kinase
B; ERK, extracellular signal-regulated kinase, MEK, MAP kinase kinase;
mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin
homolog deleted on chromosome 10; PGG2, prostaglandin G2; PGH2,
prostaglandin H2; PI3K, phosphatidylinositol-3-kinase; RAF, rapidly
accelerated fibrosarcoma; RAS, rat sarcoma; RTK, receptor tyrosine kinase.
exon 20, usually in a ratio of 3:1 to 5:1 and few tumors (<5%) har-
bor both mutations (19–21). Interestingly, detailed analysis have
shown a gradual decrease of PIK3CA mutation from the proxi-
mal (cecum/colon ascendens) to the distal (sigma/rectum) site of
colon from 21–25% down to 8–9%, respectively (19, 20). Further-
more, PIK3CA mutated CRC has been associated with a mucinous
histological phenotype (15, 19, 20). In contrast to other molecular
markers, namely BRAF and KRAS, which are mutually exclusive,
PIK3CA mutations have shown in the majority of studies to be sig-
nificantly associated with KRAS mutation and the loss of MGMT
(O6-methylguanine-DNA methyltransferase) expression (15, 19,
20). Less consistent or no correlations where reported for CIMP-
H, MSI-H, and BRAF mutations (19, 20, 22). In an early study by
Ogino and co-workers analyzing patients with curatively resected
CRC stage I–III, mutations in PIK3CA were detected in 18% and
reported to be associated with a significant worse outcome. This
effect, however, was restricted to tumors with wild-type KRAS
(14). Similar results were reported in other patient collectives naïve
to anti-EGFR therapy with a frequency of PI3KCA mutation rang-
ing from 12 to 13%; but again, this correlation with poor outcome
was restricted to KRAS wild-type tumors (16, 23). Further studies,
taking in consideration a broader range of molecular markers, did
not confirm these previous data for PIK3CA, being an independent
prognostic marker for CRC. Mouradov and co-worker analyzed
the disease free survival (DFS) in 822 patients with CRC stage II/III
and correlated this data with MSI, CIN, and a number of molec-
ular biomarkers, including PIK3CA (18). In this study, only CIN
and MSI were associated with DFS but with none of the molecular
biomarkers, including PIK3CA (18). Similarly, in a Scandinavian
evaluation, analyzing two study cohorts of 611 patients, PIK3CA
did not show any prognostic impact (24). In this study, however,
the molecular analysis of PIK3CA was restricted to exon 20, leading
to the expected low frequency of 2.2% PIK3CA mutated tumors.
The rationale behind this approach is that some studies have sug-
gested that the poor prognosis of PIK3CA is restricted to exon
20 mutations and that the analysis of exon 9 may produce false
positive results due to presence of pseudogenes (25, 26). Indeed,
in breast cancer, the prognostic impact of PIK3CA has been simi-
larly reported to be restricted to exon 20 (27, 28). This concept is
supported by in vitro studies showing that mutations in the helical
(exon 9) and kinase (exon 20) domain use different and inde-
pendent mechanisms for cell transformation (29). In addition, the
effect of PIK3CA mutation is RAS dependent in the helical but not
the kinase domain, which may explain the stronger association of
KRAS mutation with exon 9 mutations of PIK3C (19, 22). Taken
together, mutation of PIK3CA in CRC may have a slight prognos-
tic impact in anti-EGFR naïve patients; the extent, if present, of
this impact, however, especially in respect to different mutations,
remains to be clarified.
PIK3CA AS PREDICTIVE MARKER IN ANTI-EGFR THERAPY
Despite the fact that CRC can curably be treated at early stages,
advanced tumors, namely metastatic cancer are associated with a
high mortality rate and a 5-year survival of below 10% (30). The
introduction of a targeted therapy using monoclonal anti-EGFR
antibody, namely panitumumab and cetuximab, in combination
chemotherapy or as a single agent, has added a further promising
treatment option (4, 31). However, only a subgroup of patients,
usually <10% in unselected patients, profit of anti-EGFR anti-
body treatment (5, 32). Several clinical trials have shown that RAS
mutations are the most important negative predictive factor in
CRC, primarily mutations in exon 1 and 2 of RAS, but, as recently
been shown, also of exon 3 and 4 of KRAS and NRAS, respec-
tively (32, 33). However, even in wild-type RAS tumors, 50–60%
of patients do not profit from an anti-EGFR therapy. Based on the
well-established pathway of the EGFR receptor, other downstream
elements of the direct or associated signaling pathway, including
BRAF/MEK/ERK and PIK3/PTEN/AKT/mTOR have been ana-
lyzed as potential biomarker (Figure 1). In a first study, analyzing
110 patients with CRC, Sartore-Bianchi and co-workers reported
a significant resistance to EGFR-targeted therapy in the 13.6% of
PIK3CA mutated cancers (34). The predictive value of PIK3CA
mutation in RAS wild-type CRC was supported subsequent by
additional studies (35, 36). Interestingly, however, in a study by
Prenen and co-workers analyzing 200 chemorefractory patients
treated with cetuximab, PIK3CA mutation, detected in 11.5% of
tumors, was no predictor of anti-EGFR response (37). Further
detailed studies, analyzing PIK3CA mutation of exon 9 and exon
20 separately, may possibly give the explanation for the discrepancy
of the predictive value of PIK3CA as a biomarker for anti-EGFR
response. In a carefully performed, retrospective study including
743 CRC, de Roock and co-workers describe in KRAS wild-type
tumors a significant association of objective response, overall sur-
vival, and progression free survival in exon 20 but not in exon 9
mutated tumors (22). As expected, the incidence of exon 20 muta-
tion in PIK3CA was low, i.e., 3.0%, however, the mutation analysis
added another 1.3% improvement of anti-EGFR response predic-
tion, similar to the improvement of prediction by testing NRAS
(i.e., 1.5%) (22).
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PIK3CA AS BIOMARKER FOR ADJUVANT ASPIRIN THERAPY
Based on several observational studies as well as randomized trials,
it has been long considered that aspirin is efficient in prevent-
ing colorectal adenomas and cancers (38, 39). This anti-tumor
effect is thought to be driven by the inhibition of cyclooxygenases
[COX-2, officially called HGNC:9605 or PTGS2 (prostaglandin-
endoperoxide synthase 2)], interacting with the arachidonic acid
metabolite pathway, however, the detailed mechanism of action
is not completely understood [reviewed in Ref. (40)]. This anti-
tumor effect has reported to be restricted to patients with cancers
showing an over expression of COX-2 demonstrated by immuno-
histochemistry (41). However, as 60–85% of CRCs has been
reported to over express COX-2 (42), immunohistochemistry is
considered a less reliable predictive marker for adjuvant aspirin
therapy. Due to its side effects, namely gastrointestinal irritation
and bleeding, wide spread and unselected chemoprevention by
aspirin is not recommended. In addition, more specific COX-2
inhibitors, such as rofecoxib or celecoxib, had to be withdrawn
from the market due to their cardiovascular side effects. Therefore,
the recent study by Liau and co-workers, reporting an improved
survival of CRC patients using regular aspirin in tumors harbor-
ing a PIK3CA mutation, has created a lot of interest (13). Using
data of two large prospective studies, the Nurses’ Health study and
the Health Professionals Follow-up Study, the authors were able
to follow 964 patients for a median follow-up time of 153 months.
PIK3CA mutations were detected in 16.7% of tumors, and in the
patients with mutated cancer, the regular use of aspirin was asso-
ciated with a reduction of tumor specific and over all mortality
of 82 and 46%, respectively. The precise molecular and biologi-
cal mechanisms of aspirin to the PIK3/AKT/mTOR pathway have
to be clarified in detail (Figure 1). In vitro studies indicate that
the PIK3CA induces the expression of COX-2 (43). In addition,
COX unrelated effects, namely the change of the microenviron-
ment and subsequently the intestinal microbioma in the gut as
well as the anti-thrombotic effect of aspirin, which may be rel-
evant in the development of metastasis, have to be considered
(44, 45). An additional clinical study by Domingo and co-workers,
again retrospectively analyzing a large prospective study cohort of
896 patients with CRC, the patients of the VICTOR trial, has con-
firmed the predictive value of PIK3CA mutation for taking aspirin
in an adjuvant setting (46). Interestingly, however, this effect could
not be observed in patients taken the specific COX-2 inhibitor
rofecoxib. These data indicate that the predictive value of PIK3CA
mutation goes beyond COX-2 inhibition and underlies the impor-
tance of a COX-independent effect of aspirin in the prevention
of cancer development and spread. Despite the promising results
reported by these two studies, there is some caveat to express: based
on the stratification necessary, i.e., patients with PIK3CA mutated
tumors and taking regularly aspirin, the numbers of patients is
relatively small in both studies (60 and 45 patients, respectively)
and prospective, large scale clinical trials are needed to confirm
this data, highly relevant for the future management of patients
with CRC.
In conclusion, somatic mutations of PIK3CA are present in 10–
20% of CRC, basically confined to exon 9 and exon 20 (or more
precisely, these are the exons usually analyzed). The majority of
studies are based on pooled data in respect to the exon mutated,
but experimental as well as epidemiological evidence point in the
direction that mutation in exon 20 but not in exon 9 may be
biologically relevant. So far, mutation of PIK3CA as a single prog-
nostic marker seems to have, if some, a minor effect of the overall
prognosis of CRC but a small and distinct predictive impact for
anti-EGFR therapy in RAS wild-type tumors. In addition, there is
strong evidence of the predictive value of PIK3CA mutations for
adjuvant therapy using aspirin, however, further data are needed to
definitively define the impact of, especially exon specific, PIK3CA
mutation in the management of patients with CRC.
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